Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
P & T Update Memo September 2018

Following is a P and T Committee update (from the September 25th meeting). Starting date for specific programs is 1 Oct 2018, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red. 

Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.

 

Drug or Drug Class

Formulary Decision

Comments
fostamatinib (Tavalisse) Non-Formulary Inpatients may use own supply.
ivosidenib (Tibsovo) Non-Formulary Inpatients may use own supply. Defer initiation until after hospital discharge.
axicabtagene ciloleucel (Yescarta) Non-Formulary Initiation of therapy must be done at an approved, certified regional site.
Pertuzumab (Perjeta) Referred to High Value Care Committee If approved, use will be restricted to outpatient infusion areas.
filgrastim-aafi (Nivestym)

Formulary


Therapeutic Equivalent to Neupogen, Granix, & Zarxio

 An expanded automatic interchange among filgrastim agents based on economic considerations was approved. Pediatric use pending as St. Jude has not yet evaluated the new biosimilar.
Aripiprazole lauroxil (Aristada Intio) Formulary, Restricted Restricted to use by psychiatry utilizing a no-charge dose initiation program sponsored by the drug company.
apentadol (Nucynta & Nucynta ER) Formulary Reclassified as formulary due to
increased utilization in the community
and classification as a controlled
substance, schedule II.
Insulin human, injection 500 units/mL (Humulin R U-500)

PEN: Formulary, Restricted


VIAL: Non-Formulary

Restricted to continuation of home
therapy. Initiation of the 500 units/mL
formulation must be deferred until after discharge.


Only the PEN formulation will be
utilized within the hospital due to
potential medication safety concerns
with the VIAL. Inpatients may use their
own supply of the PEN, but the VIAL
formulation must be interchanged to a
pharmacy-dispensed PEN. PENs are not routinely stocked.
Aristada Order Set Order Set Approved Build in Cerner pending.


 

 

 

 

 

 

 






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved